 |
26 Diseases |  |
30 Trials |
|
30 Trials |  |
518 News |  |
| «12345678910111213 |
- CIML NK cells / Washington University School of Medicine in St. Louis
Trial initiation date, Trial primary completion date: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (clinicaltrials.gov) - Nov 25, 2016
P2, N=60, Not yet recruiting, Sponsor: Washington University School of Medicine
Initiation date: Aug 2016 --> Jan 2017 | Trial primary completion date: Nov 2019 --> Apr 2020
- Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P1 trial, Combination therapy: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 (clinicaltrials.gov) - Sep 7, 2016
P1, N=27, Not yet recruiting, Sponsor: David Wald
- |||| Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment open, Combination therapy, Metastases: QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel (clinicaltrials.gov) - Aug 22, 2016
P1/2, N=66, Recruiting, Sponsor: Altor Bioscience Corporation
Initiation date: Aug 2016 --> Jan 2017 | Trial primary completion date: Nov 2019 --> Apr 2020 Not yet recruiting --> Recruiting
- CIML NK cells / Washington University School of Medicine in St. Louis
Trial primary completion date: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Aug 15, 2016
P1, N=24, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2016 --> Dec 2016
- ||| Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment change, Combination therapy, IO biomarker: QUILT-2.005: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Aug 12, 2016
P1/2, N=81, Recruiting, Sponsor: Altor Bioscience Corporation
Trial primary completion date: Aug 2016 --> Dec 2016 N=115 --> 81
- Anktiva (inbakicept) / ImmunityBio
Trial primary completion date: ALT-803: Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People (clinicaltrials.gov) - Jul 19, 2016
P1, N=10, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
N=115 --> 81 Trial primary completion date: Jun 2016 --> Oct 2016
- Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial primary completion date, Metastases: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 19, 2016
P1, N=20, Recruiting, Sponsor: Altor Bioscience Corporation
Trial primary completion date: Jun 2016 --> Oct 2016 Trial primary completion date: Jun 2016 --> Oct 2016
- Anktiva (inbakicept) / ImmunityBio
Enrollment open: ALT-803: Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People (clinicaltrials.gov) - Jun 27, 2016
P1, N=10, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Trial primary completion date: Jun 2016 --> Oct 2016 Not yet recruiting --> Recruiting
- CIML NK cells / Washington University School of Medicine in St. Louis
Trial primary completion date: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jun 1, 2016
P1, N=24, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2016 --> Aug 2016
- | CIML NK cells / Washington University School of Medicine in St. Louis
New P2 trial: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation (clinicaltrials.gov) - May 25, 2016
P2, N=60, Not yet recruiting, Sponsor: Washington University School of Medicine
- ||| Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel (clinicaltrials.gov) - Mar 4, 2016
P1/2, N=66, Not yet recruiting, Sponsor: Altor Bioscience Corporation
Trial primary completion date: Apr 2016 --> Aug 2016 Initiation date: Oct 2015 --> Apr 2016 | Trial primary completion date: Oct 2018 --> Apr 2019
- |||| Opdivo (nivolumab) / BMS, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment open: ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 22, 2016
P1/2, N=91, Recruiting, Sponsor: John Wrangle
Initiation date: Oct 2015 --> Apr 2016 | Trial primary completion date: Oct 2018 --> Apr 2019 Not yet recruiting --> Recruiting
- CIML NK cells / Washington University School of Medicine in St. Louis
Trial primary completion date: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jan 17, 2016
P1, N=24, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Apr 2016
- Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial primary completion date: IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=61, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Dec 2015 --> Apr 2016 Trial primary completion date: Nov 2015 --> Jun 2017
- ||||| Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P1/2 trial, Combination therapy, Metastases: QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel (clinicaltrials.gov) - Sep 24, 2015
P1/2, N=66, Not yet recruiting, Sponsor: Altor Bioscience Corporation
- | CST-101 / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment open, Combination therapy, Metastases: QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) (clinicaltrials.gov) - Aug 18, 2015
P2, N=24, Recruiting, Sponsor: Conkwest, Incorporated
Trial primary completion date: Nov 2015 --> Jun 2017 Not yet recruiting --> Recruiting
- ||||| Opdivo (nivolumab) / BMS, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P1/2 trial: ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 14, 2015
P1/2, N=91, Not yet recruiting, Sponsor: John Wrangle
- ||| Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment change, Combination therapy, IO biomarker: QUILT-2.005: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Aug 11, 2015
P1/2, N=115, Recruiting, Sponsor: Altor Bioscience Corporation
Not yet recruiting --> Recruiting N=18 --> 115
- CST-101 / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P2 trial, Combination therapy, Metastases: QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) (clinicaltrials.gov) - Jun 9, 2015
P2, N=24, Not yet recruiting, Sponsor: Conkwest, Incorporated
- ||||| Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P1/2 trial, IO biomarker: QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab (clinicaltrials.gov) - Mar 10, 2015
P1/2, N=75, Recruiting, Sponsor: Altor Bioscience Corporation
- | Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment open, Trial initiation date, Trial primary completion date, IO biomarker: QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 11, 2014
P1/2, N=50, Recruiting, Sponsor: Altor Bioscience Corporation
N=18 --> 115 Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Sep 2014 | Trial primary completion date: Apr 2016 --> Sep 2016
- CIML NK cells / Washington University School of Medicine in St. Louis
Enrollment open: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Aug 15, 2014
P1, N=24, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Sep 2014 | Trial primary completion date: Apr 2016 --> Sep 2016 Not yet recruiting --> Recruiting
- | Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment open, Combination therapy, IO biomarker: QUILT-2.005: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Jul 30, 2014
P1/2, N=18, Recruiting, Sponsor: Altor Bioscience Corporation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Anktiva (inbakicept) / ImmunityBio
New P1 trial: ALT-803: Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People (clinicaltrials.gov) - Jul 16, 2014
P1, N=10, Not yet recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
- CIML NK cells / Washington University School of Medicine in St. Louis
Enrollment change: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jun 26, 2014
P1, N=48, Not yet recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting N=24 --> 48
- | Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P1/2 trial, Combination therapy, IO biomarker: QUILT-2.005: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov) - May 13, 2014
P1/2, N=18, Not yet recruiting, Sponsor: Altor Bioscience Corporation
- Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial initiation date, Metastases: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 17, 2014
P1, N=20, Recruiting, Sponsor: Altor Bioscience Corporation
N=24 --> 48 Initiation date: Jan 2014 --> Apr 2014
- Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment open, Metastases: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 17, 2014
P1, N=20, Recruiting, Sponsor: Altor Bioscience Corporation
Initiation date: Jan 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- | Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P1/2 trial, IO biomarker: QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 27, 2014
P1/2, N=50, Not yet recruiting, Sponsor: Altor Bioscience Corporation
- Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial initiation date: IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT (clinicaltrials.gov) - Nov 10, 2013
P1/2, N=61, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Not yet recruiting --> Recruiting Initiation date: Jun 2013 --> Nov 2013
- Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Enrollment open: IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT (clinicaltrials.gov) - Nov 10, 2013
P1/2, N=61, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Initiation date: Jun 2013 --> Nov 2013 Not yet recruiting --> Recruiting
- | Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P1 trial, Metastases: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 18, 2013
P1, N=20, Recruiting, Sponsor: Altor Bioscience Corporation
- CIML NK cells / Washington University School of Medicine in St. Louis
New P1 trial: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jul 10, 2013
P1, N=48, Not yet recruiting, Sponsor: Washington University School of Medicine
- | Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
New P1/2 trial: IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT (clinicaltrials.gov) - Jun 23, 2013
P1/2, N=61, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota